HongKong:1530

3SBio MSCI ESG Rating Upgraded to A, Ranking at the Forefront of the Global Biotechnology Industry

SHANGHAI, Sept. 2, 2020 /PRNewswire/ -- According to Morgan Stanley Capital International's (MSCI) latest set of ESG ratings forAugust 26th 2020, 3SBio has been upgraded to A status, surpassing that of 78% of companies in the global biotechnology industry. MSCI ESG ratings focus on ESG issues th...

2020-09-02 02:15 6148

3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar 45.2%

HONGKONG, March 31, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2019 annual results, showing that the Company maintained steady growth, with core products continuously leading the market and more products being included into drug reimbursemen...

2020-03-31 12:29 8167

3SBio Selects Verseau's PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration

SHENYANG, China and BEDFORD Mass., Nov. 17, 2019 /PRNewswire/ -- 3SBio Inc. ("3SBio") (HKEX:1530) and Verseau Therapeutics, Inc.  ("Verseau") today announced the selection of VTX-0811, a monoclonal antibody targeting PSGL-1, as the first lice...

2019-11-18 08:30 2567

Submission and acceptance of application for the production of new drug for Yisaipu(R)aqueous injection solution

SHANGHAI, July 29, 2019 /PRNewswire/ -- 3SBio Inc. (01530.HK), a leading biopharmaceutical company in the PRC, announces today that an application for the production of new drug has been submitted to the National Medical Products Administration for Yisaipu® pre-filled aqueous injection solution (...

2019-07-29 21:42 4345

3SBio Unveils 2018 Annual Results: Revenue Soars by 22.7%, Normalized Net Profit Soars by 29.0%, R&D Expenses Jumps Over 40%

HONG KONG, March 21, 2019 /PRNewswire/ -- Chinese leading biotechnology company 3SBio (01530.HK) today released its 2018 annual results, showing that the Company has been posting dramatic business growth, and has been gearing up R&D layout and investment in innovative drugs. Financial highlights...

2019-03-21 00:14 1414

3SBio and TLC Form Exclusive Partnership to Commercialize Two NanoX(TM) Products in Mainland China

SHENYANG, China, March 4, 2019 /PRNewswire/ -- 3SBio Inc. ("3SBio") (HKEX: 1530) and Taiwan Liposome Company, Ltd. ("TLC") (Nasdaq: TLC, TWO: 4152) today announced an exclusive partnership to commercialize in mainlandChina two liposomal products utilizing TLC's proprietary NanoX™ technology platf...

2019-03-04 07:00 3961

3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies

SHENYANG, China and BOSTON, Feb. 11, 2019 /PRNewswire/ -- 3SBio Inc. ("3SBio") (HKEX:1530) and Verseau Therapeutics, Inc. ("Verseau") announced today a partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a broad...

2019-02-11 20:19 968

3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies

SHENYANG, China and BOSTON, Feb. 11, 2019 /PRNewswire/ -- 3SBio Inc. ("3SBio") (HKEX:1530) and Verseau Therapeutics, Inc. ("Verseau") announced today a partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a broad...

2019-02-11 20:18 564

3SBio Unveils 2017 Annual Results: Revenue Soars by 33.5%

HONG KONG, March 26, 2018 /PRNewswire/ -- Leading Chinese biotechnology company 3SBio(01530.HK) today released its 2017 annual results, showing that the company has been dramatically growing with important progress made in all businesses. Looking to the future, the company intends to reinforce it...

2018-03-26 22:09 1044

China FDA Approves New Once-Weekly Bydureon(R) to Improve Glycemic Control in Patients with Type-2 Diabetes

SHANGHAI, Jan. 4, 2018 /PRNewswire/ -- 3Sbio Inc. (01530.HK) announced today thatChina's first Glucagon-like peptide-1 (GLP-1) receptor agonist weekly preparation Bydureon® (generic name Exenatide Microsphere for injection) has been formally approved by China Food and Drug Administration (CFDA), ...

2018-01-04 14:46 1145

3SBio Accelerates Expansion of its Global Biologics Platform by Acquiring the Canadian Biomanufacturing Business of Therapure

SHENYANG China, Sept. 3, 2017 /PRNewswire/ -- 3SBio Inc. (01530.HK, the "Group"), a leading Chinese biopharmaceutical company, is pleased to announce today that it has entered into a Shareholder Agreement with CPE Funds, pursuant to which a Joint Venture (the "JV") shall be established. The Group...

2017-09-03 21:01 2597

3SBio Inc. Appoints Dr. Zhenping Zhu as President of Research & Development and Chief Scientific Officer

SHENYANG, China, Jan. 9, 2017 /PRNewswire/ -- 3SBio Inc., (HKEX:1530) ("3SBio" and together with its subsidiaries the "3SBio Group") is pleased to announce thatZhenping Zhu, MD, PhD, has joined 3SBio as its new President of Research & Development and Chief Scientific Officer. "We are pleased to ...

2017-01-09 16:00 2693

3SBio Inc. Selected as a Constituent of the MSCI China Index

SHENYANG, China, May 13, 2016 /PRNewswire/ -- 3SBio Inc., (HKEX:1530) ("3SBio") today announced that according to an announcement posted on the MSCI Inc. website onMay 12, 2016, 3SBio will be added as a constituent to the MSCI China Index after the market closes onMay 31, 2016. "We are pleased ...

2016-05-13 17:00 2816

3SBio's PEG-irinotecan Wins IND Approval From China FDA

SHENYANG, China, March 7, 2016 /PRNewswire/ -- 3SBio Inc., ("3SBio") a leading biotechnology company based inChina focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has received an Investigational New Drug ("IND") approval letter ...

2016-03-07 17:24 2918

3SBio Inc. Announces Expansion of its Leadership Team

SHENYANG, China, March 4, 2016 /PRNewswire/ -- 3SBio Inc. (Hong Kong: 1530)  ("3SBio" and together with its subsidiaries the "3SBio Group") is pleased to announce thatKevin Xiao Weihong has joined 3SBio as its new chief operating officer. "We are pleased to welcome Kevin to 3SBio where he will p...

2016-03-04 19:03 3636

3SBio Signs Exclusive Patent License Agreement for ALT-P7, an Antibody-drug Conjugate Targeting HER2 with Alteogen

SHENYANG, China, and DAEJEON, Korea, Oct. 12, 2015 /PRNewswire/ -- 3SBio Inc. ("3SBio") (01530.HK), a leadingChina-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing dea...

2015-10-12 08:05 2441

3SBio Inc. Selected as a Constituent of the Hang Seng Composite LargeCap & MidCap Index

SHENYANG, China, Aug. 17, 2015 /PRNewswire/ -- 3SBio Inc., (HKEX: 1530) ("3SBio") today announced that effectiveSeptember 14, 2015, it will be added as a constituent of the Hang Seng LargeCap & MidCap Index according to a press release issued by Hang Seng Indexes Company Limited ("Hang Seng") o...

2015-08-17 22:46 1907

3SBio Acquires Zhejiang Wansheng Pharmaceutical

SHENYANG, China, July 24, 2015  /PRNewswire/ -- - Adds integrated small molecule drug R&D and manufacturing platform - Expands product offering for chronic kidney disease and oncology patients - Further addresses unmet medical needs in diabetes-related complications and dermatology - Increas...

2015-07-24 17:07 3145

3SBio Acquires Global Rights to Anti-TNF mAb

SHENYANG, China, June 22, 2015 /PRNewswire/ -- 3SBio Inc., (HKEX: 1530) ("3SBio"), a leadingChina-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's ...

2015-06-22 20:55 2696